Plasma levels of amyloid β proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome

Annals of Neurology

Volumn 41, Issue 2, 1997, Pages 271-273

  Tokuda, Takahiko ^a   Fukushima, Tetsuro ^b   Ikeda, Shu Ich ^a   Sekijima, Yoshiki ^a   Shoji, Shin'ichi ^b   Yanagisawa, Nobuo ^a   Tamaoka, Akira ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DOSAGE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AMYLOID BETA-PROTEIN PRECURSOR; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0031056184     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410220     Document Type: Article

References (17)

1. Kang J, Lemire H-G, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736
2. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-325
3. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992;258:126-129
4. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 1992;359:325-327
5. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 1992;267:17082-17086
6. Roher AE, Lowenson JD, Clark S, et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268:3072-3083
7. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implication for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-4697
8. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994;13:45-53
9. Tamaoka A, Sawamura N, Odaka A, et al. Amyloid β protein (Aβ1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res 1995;679:151-156
10. Suzuki N, Cheung IT, Cai X-D, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 1994;264:1336-1340
11. Tamaoka A, Odaka A, Ishibashi Y, et al. APP717 missense mutation affects the ratio of amyloid β protein species (Aβ1-42/43 and Aβ1-40) in familial Alzheimer's disease brain. J Biol Chem 1994;269:32721-32724
12. Mann DMA, Iwatsubo T, Ihara Y, et al. Predominant deposition of amyloid β42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996;148:1257-1266
13. Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 1989;320:1446-1452
14. Ikeda S, Yanagisawa N, Allsop D, Glenner GG. Evidence of amyloid β-protein immunoreactive early plaque lesions in Down's syndrome brains. Lab Invest 1989;61:133-137
15. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med 1996;2:93-95
16. Tamaoka A, Kondo T, Odaka A, et al. Biochemical evidence for the long-tail form (Aβ1-42/43) of amyloid β protein as a seed molecule cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994;205:834-842
17. Iwatsubo T, Mann DMA, Odaka A, et al. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol 1995;37:294-299